News Briefing channel feed

FDA OKs new la­bel ex­pan­sions for Dupix­ent and In­cyte's Mon­ju­vi

8 hours ago

Bavar­i­an Nordic's PRV goes for $160M; Bio­mea to ad­vance GLP-1 in­to tri­als

2 days ago

Prothena moves for­ward with lay­offs; Aldeyra re­sub­mits dry eye drug to FDA

3 days ago

In­cyte’s promis­ing throm­bo­cythemia drug; Cres­cent Bio­phar­ma rais­es $200M in PIPE

4 days ago

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

Last week

ADC Ther­a­peu­tics re­veals lay­offs, $100M PIPE; Third Har­mon­ic seeks buy­er for as­set

Last week

Lil­ly pledges more than $650M to mus­cle health biotech; Co­gent gets $50M

Last week

In­smed’s stock ral­lies on PAH da­ta; Uni­cy­cive aims to re­solve CD­MO is­sues

Last week

Avid­i­ty to seek ac­cel­er­at­ed ap­proval for FSHD drug; Ax­some to run an­oth­er tri­al

Last week

Kelun's $250M PIPE; Val­ne­va moves chikun­gun­ya vac­cine to Phase 3 for kids

2 weeks ago

Cul­li­nan's deal for T cell en­gager from Chi­na; Kardi­gan buys late-stage heart drug

3 weeks ago

Vig­il drug fails a Phase 2; Merus aims to raise $300M

3 weeks ago

Ve­ra re­draws the terms of up to $500M cred­it fa­cil­i­ty; Tre­vi aims to raise $100M

3 weeks ago

Sanofi pays out two STAT6 mile­stones; Ther­a­vance sells more Trel­e­gy roy­al­ties

3 weeks ago

Roche’s 96-week da­ta for mul­ti­ple scle­ro­sis drug; ZymeWorks claims $20M mile­stone

3 weeks ago

Taysha’s piv­otal tri­al plans; Keros to stop work on PAH drug, lay off 45% of staff

4 weeks ago

Veru’s obe­si­ty drug rough­ly as safe as We­govy; Keros’ board fight

4 weeks ago

ITM re­veals up to $262M debt fi­nanc­ing; Caris Life Sci­ences to go pub­lic

4 weeks ago

GLP-1s may cut can­cer risk; Gyre’s stock falls af­ter hep B da­ta and of­fer­ing

4 weeks ago

Mod­er­na pulls ap­pli­ca­tion for Covid-flu shot; An­oth­er IPO in Hong Kong

5 weeks ago

SV Health’s $269M de­men­tia fund; Schrödinger lays off 7% of staff

Last month

Io­n­is de­tails late-stage da­ta for heart drug; Ar­ma­ta’s promis­ing staph in­fec­tion ther­a­py

Last month

FDA lifts hold on Scynex­is tri­al; In­cyte’s Zynyz notch­es an­oth­er FDA ap­proval

Last month

En­liv­en stops work on sol­id tu­mor drug; Pul­ma­trix to di­vest as­sets

Last month
1234 Next page Last page
A service from the Financial Times